A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
Status:
Completed
Trial end date:
2012-03-14
Target enrollment:
Participant gender:
Summary
This open-label study will assess the safety and efficacy of RO5185426 in previously treated
metastatic melanoma patients with brain metastases. Patients will receive RO5185426 at a dose
of 960 mg twice daily orally until disease progression or unacceptable toxicity occurs.